PIZENSY Drug Patent Profile
✉ Email this page to a colleague
When do Pizensy patents expire, and what generic alternatives are available?
Pizensy is a drug marketed by Braintree Labs and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in PIZENSY is lactitol. There are four drug master file entries for this compound. Additional details are available on the lactitol profile page.
DrugPatentWatch® Generic Entry Outlook for Pizensy
Pizensy was eligible for patent challenges on February 12, 2024.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 12, 2025. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PIZENSY?
- What are the global sales for PIZENSY?
- What is Average Wholesale Price for PIZENSY?
Summary for PIZENSY
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 60 |
| Patent Applications: | 3,047 |
| What excipients (inactive ingredients) are in PIZENSY? | PIZENSY excipients list |
| DailyMed Link: | PIZENSY at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PIZENSY
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for PIZENSY
PIZENSY is protected by one US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of PIZENSY is ⤷ Sign Up.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting PIZENSY
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.
FDA Regulatory Exclusivity protecting PIZENSY
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Braintree Labs | PIZENSY | lactitol | FOR SOLUTION;ORAL | 211281-001 | Feb 12, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Braintree Labs | PIZENSY | lactitol | FOR SOLUTION;ORAL | 211281-001 | Feb 12, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
